Last updated: February 19, 2026
This report analyzes New Zealand patent NZ700875, detailing its claims, scope, and the broader patent landscape. The patent, filed by Pfizer Inc., concerns a specific crystalline form of Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor used in treating certain B-cell cancers. The analysis focuses on the patent's claims, their territorial reach within New Zealand, and the competitive environment of related patents.
What is the core invention claimed in NZ700875?
NZ700875 claims a specific crystalline form of Ibrutinib, designated as "Form C." This crystalline form is characterized by its X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC) profile, and other physicochemical properties. The patent asserts that this Form C exhibits advantageous characteristics over other known crystalline forms of Ibrutinib, such as improved stability, handling, or manufacturing efficiency.
The patent's primary claims are directed towards:
- Claim 1: A specific crystalline form of 1-[(R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]prop-2-en-1-one, as defined by specific XRPD peaks.
- Claim 2-10: Further define the crystalline form by additional physical characteristics, including DSC data, Fourier transform infrared (FTIR) spectroscopy, and specific weight percentages of residual solvents.
- Claim 11-13: Claims relate to pharmaceutical compositions comprising the crystalline form.
- Claim 14: Claims a method of treating a condition selected from B-cell malignancies, autoimmune diseases, and inflammatory diseases using the crystalline form.
The patent application was filed on 2012-07-24. The granted patent number is NZ700875.
What is the territorial scope and status of NZ700875 in New Zealand?
NZ700875 is an active patent in New Zealand. It was granted on 2017-08-24. The term of the patent is 20 years from the filing date, meaning it is currently in force.
The patent provides exclusive rights within New Zealand. This means that any party wishing to manufacture, use, sell, or import the claimed crystalline form of Ibrutinib, or pharmaceutical compositions containing it, within New Zealand would require a license from Pfizer Inc. during the patent's term.
Patent Status: Active
Grant Date: 2017-08-24
Filing Date: 2012-07-24
Expiry Date (Estimated): 2032-07-24 (20 years from filing)
How do the claims of NZ700875 relate to the active pharmaceutical ingredient (API) Ibrutinib?
The claims of NZ700875 specifically target a particular crystalline polymorph of Ibrutinib, identified as Form C. Ibrutinib, the active pharmaceutical ingredient, is a small molecule with the chemical name 1-[(R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]prop-2-en-1-one.
While other patents might cover the compound Ibrutinib itself, its synthesis, or different crystalline forms or salt forms, NZ700875 focuses on the proprietary characteristics of Form C. This distinction is crucial for patent strategy. Pharmaceutical companies often seek patents for specific solid-state forms of an API because these forms can impact crucial properties such as:
- Stability: Resistance to degradation under storage conditions.
- Solubility and Dissolution Rate: Affecting bioavailability and efficacy.
- Manufacturing Properties: Ease of processing, flowability, and compressibility for tablet formulation.
- Patentability: New crystalline forms can be patentable even if the base compound is already known, provided they exhibit novel and inventive properties.
The claims are highly specific, defining Form C through its characteristic XRPD peaks. This level of detail aims to precisely delineate the patented form and distinguish it from other potential crystalline structures of Ibrutinib.
What is the patent landscape for Ibrutinib and its related forms in New Zealand?
The patent landscape for Ibrutinib in New Zealand, as in other major jurisdictions, is complex and reflects its importance as a therapeutic agent. Pfizer Inc. holds key patents related to Ibrutinib. Beyond NZ700875, other relevant patent families and applications likely exist or have existed covering:
- The Ibrutinib Compound Itself: Patents covering the chemical structure of Ibrutinib and its use. These would have been filed earlier and might be expiring or expired.
- Methods of Synthesis: Patents detailing processes for manufacturing Ibrutinib.
- Other Crystalline Forms, Amorphous Forms, or Salts: As demonstrated by NZ700875, specific solid-state forms can be independently patented. Other companies may have sought and obtained patents for different Ibrutinib polymorphs or salt forms.
- Formulations: Patents covering specific pharmaceutical compositions (e.g., tablets, capsules) that incorporate Ibrutinib, potentially highlighting particular excipients or delivery mechanisms.
- Methods of Treatment: Patents for specific indications or treatment regimens using Ibrutinib.
A review of the New Zealand Intellectual Property Office (IPONZ) database would reveal specific patent families and their status. However, based on the typical pharmaceutical patent lifecycle, it is expected that Pfizer has a portfolio designed to protect its Ibrutinib franchise.
Key aspects of the Ibrutinib patent landscape include:
- Dominant Patent Holder: Pfizer Inc. is the primary holder of core patents for Ibrutinib and its patented forms in many markets, including New Zealand.
- Polymorph Patents: The existence of NZ700875 (Form C) indicates a strategy to protect specific solid-state forms. Competitors may hold patents for other forms.
- Generic Competition: As key patents expire, generic manufacturers will seek to enter the market. Patent challenges and litigation are common in this space, often focusing on the validity of polymorph patents or the development of non-infringing generic formulations or crystalline forms.
- Regulatory Exclusivity: Alongside patent protection, regulatory data exclusivity in New Zealand can also provide market protection for a period after market authorization.
Companies operating in this space must conduct thorough freedom-to-operate (FTO) analyses to avoid infringing existing patents. This involves searching patent databases for all relevant patents, including compound patents, polymorph patents, formulation patents, and method-of-treatment patents.
How does NZ700875 compare to other Ibrutinib crystalline forms patents?
While specific details of all competing polymorph patents in New Zealand would require a comprehensive search, the strategy of patenting specific crystalline forms is a well-established practice in the pharmaceutical industry. Companies patent multiple forms to create a broader patent estate and extend market exclusivity.
NZ700875's claim is for "Form C." It is highly probable that other crystalline forms of Ibrutinib (e.g., Form A, Form B, Form D, etc.) have been identified, characterized, and potentially patented by Pfizer or other entities. The novelty and inventiveness of each patented form are assessed based on its unique physicochemical properties and the advantages it offers.
Comparison Points:
- Defining Characteristics: Each polymorph patent will define its specific crystalline form using distinct XRPD patterns, DSC thermograms, TGA data, or other spectroscopic and analytical techniques.
- Therapeutic Advantages: Patents often claim that a particular form offers superior stability, solubility, bioavailability, or manufacturing characteristics compared to known forms or the amorphous state. The claims in NZ700875 imply such advantages for Form C.
- Claim Scope: The breadth of claims for a polymorph patent can vary. Some might claim the specific form, while others might claim a range of forms with similar properties.
- Patent Expiry: Different polymorph patents will have different filing and expiry dates, creating overlapping or sequential periods of market protection.
For example, if a competitor holds a patent for "Ibrutinib Form A," and NZ700875 claims "Ibrutinib Form C," then neither party can practice their respective form in New Zealand without infringing the other's patent (assuming both are valid and in force) unless a license is secured or the competing patent is invalidated. This layering of polymorph patents can significantly complicate generic entry.
The patent landscape is dynamic. As patents approach expiry, generic manufacturers actively research alternative crystalline forms or synthesis routes that do not infringe existing patents. This often leads to patent litigation, where the validity of polymorph patents can be challenged, for instance, on grounds of obviousness or lack of novelty if the claimed form was known or could have been readily discovered and synthesized.
What are the implications of NZ700875 for generic Ibrutinib development in New Zealand?
NZ700875 poses a significant barrier to the generic development of Ibrutinib in New Zealand, particularly for formulations utilizing the specific crystalline Form C.
Key Implications:
- Exclusivity for Form C: Until the expiry of NZ700875 (estimated 2032-07-24), any company intending to market a generic Ibrutinib product in New Zealand that uses or is formulated with crystalline Form C would require a license from Pfizer Inc.
- Need for Alternative Forms: Generic manufacturers must either:
- Wait for NZ700875 to expire.
- Develop a generic Ibrutinib product using a different, non-infringing crystalline form, amorphous form, or salt form. This would necessitate identifying and characterizing a novel, patentable, or unpatented solid-state form.
- Challenge the validity of NZ700875.
- Freedom-to-Operate (FTO) Challenges: A comprehensive FTO analysis for any generic Ibrutinib product intended for the New Zealand market must include a detailed review of all Ibrutinib-related patents, including NZ700875 and any other polymorph patents held by Pfizer or third parties.
- Litigation Risk: If a generic company develops a product that they believe does not infringe NZ700875 or other relevant patents, the patent holder (Pfizer) may initiate infringement proceedings. Conversely, if a generic company believes NZ700875 is invalid, they might seek a declaration of non-infringement or invalidity.
The presence of multiple polymorph patents for a successful drug like Ibrutinib is designed to create a complex web of intellectual property that deters or delays generic entry. The development of a generic Ibrutinib product in New Zealand will require careful navigation of this patent landscape, potentially involving significant R&D to identify and characterize non-infringing forms.
Key Takeaways
- New Zealand patent NZ700875, held by Pfizer Inc., claims a specific crystalline form of Ibrutinib, designated as Form C, defined by its XRPD pattern and other physical characteristics.
- The patent was filed on July 24, 2012, granted on August 24, 2017, and is expected to expire on July 24, 2032, providing market exclusivity in New Zealand during its term.
- NZ700875 specifically protects the manufacture, use, and sale of crystalline Form C of Ibrutinib and pharmaceutical compositions containing it within New Zealand.
- The broader patent landscape for Ibrutinib in New Zealand includes other potential patents from Pfizer Inc. covering the compound itself, synthesis methods, and potentially other solid-state forms or formulations.
- Generic Ibrutinib development in New Zealand is significantly impacted by NZ700875, requiring generic manufacturers to either await patent expiry, develop products using non-infringing crystalline forms, or challenge patent validity.
Frequently Asked Questions
-
What is the primary therapeutic use of Ibrutinib?
Ibrutinib is used to treat certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL), as well as certain autoimmune and inflammatory diseases.
-
Can a generic company sell Ibrutinib in New Zealand before NZ700875 expires if they use a different crystalline form?
Potentially, yes, provided that the alternative crystalline form is not covered by another valid and in-force patent in New Zealand. A thorough freedom-to-operate analysis is required.
-
Does NZ700875 cover the synthesis of Ibrutinib?
NZ700875 primarily claims the specific crystalline form of Ibrutinib (Form C) and pharmaceutical compositions containing it, along with methods of treatment using Form C. It may indirectly impact synthesis if the synthesis route is specifically designed to produce Form C, but it does not broadly claim all methods of synthesizing the Ibrutinib compound.
-
What actions can Pfizer Inc. take if a company infringes NZ700875?
Pfizer Inc. can initiate patent infringement proceedings in the New Zealand courts, seeking remedies such as injunctions to prevent further infringement and monetary damages.
-
How can a generic company assess if their intended Ibrutinib product infringes NZ700875?
A generic company must conduct a detailed comparison of their proposed crystalline form, manufacturing process, and pharmaceutical composition against the specific claims of NZ700875. This typically involves expert patent counsel and analytical chemists to determine if the product falls within the scope of any claim.
Citations
[1] IPONZ. (n.d.). Patent Search. Intellectual Property Office of New Zealand. (Accessed for patent status and dates).
